antibody-therapeutics
(2)
Hinge Bio
Hinge Bio is a clinical-stage biotechnology company in Burlingame, California, building next-generation antibody therapeutics on its proprietary GEM-DIMER platform. The platform engineers multivalent, multispecific antibodies that bind their targets cooperatively for dramatically enhanced potency. Its lead candidate, HB2198, is a B cell-depleting agent targeting both CD19 and CD20 with enhanced natural killer cell engagement, now in Phase 1 trials for systemic lupus erythematosus and lupus nephritis. The company raised a $30M Series A led by Point72 in January 2025.
Peyton Greenside
Peyton Greenside is the CEO and co-founder of BigHat Biosciences, a San Mateo-based biotech company she co-founded in 2019 with Mark DePristo. A pioneer of deep learning applied to life science, Greenside combined a PhD in Biomedical Informatics from Stanford, an MPhil from Cambridge, and a BA in Applied Math from Harvard into a singular mission: use machine learning and synthetic biology to design safer, more effective antibody therapeutics faster than anyone thought possible. BigHat's Milliner platform generates thousands of unique antibody designs per week, and the company has raised $174M in total funding with pharma partnerships spanning Amgen, Merck, AbbVie, Johnson & Johnson, and Eli Lilly.